Literature DB >> 34149211

Ovarian Cancer Stem Cells: Newer Horizons.

Mala Srivastava1, Neha Ahlawat1, Ankita Srivastava1.   

Abstract

The ovarian cancer is one of the frequent cancers among women being diagnosed after cervical and breast cancer. The CA ovary is dreaded because even after successful treatment of the primary malignancy, the disease comes back and becomes resistant to conventional management. The prognosis in ovarian cancer management is mostly unsatisfactory, maybe because of the presence of ovarian cancer stem cells (OCSC). The hypothesis is that OCSC causes the recurrence of the ovarian malignancy. The OCSC can be identified by the presence of different markers and marker combinations. The assumptions are that CD44+, CD24+, CD117+, CD133+ and ALDH1+ could be the markers of ovarian cancer stem cells. The epithelial ovarian malignancy if proved as a stem cell disease, then it changes the entire management scenarios. Maybe, this will be the first step in managing the ovarian malignancy in the future. © Federation of Obstetric & Gynecological Societies of India 2021.

Entities:  

Keywords:  Aggressiveness; Cancer; Ovarian; Recurrence; Stem cells

Year:  2021        PMID: 34149211      PMCID: PMC8166988          DOI: 10.1007/s13224-020-01412-7

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  18 in total

1.  Rethinking ovarian cancer: recommendations for improving outcomes.

Authors:  Sebastian Vaughan; Jermaine I Coward; Robert C Bast; Andy Berchuck; Jonathan S Berek; James D Brenton; George Coukos; Christopher C Crum; Ronny Drapkin; Dariush Etemadmoghadam; Michael Friedlander; Hani Gabra; Stan B Kaye; Chris J Lord; Ernst Lengyel; Douglas A Levine; Iain A McNeish; Usha Menon; Gordon B Mills; Kenneth P Nephew; Amit M Oza; Anil K Sood; Euan A Stronach; Henning Walczak; David D Bowtell; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

Review 2.  Clinical practice. Screening for ovarian cancer.

Authors:  Daniel L Clarke-Pearson
Journal:  N Engl J Med       Date:  2009-07-09       Impact factor: 91.245

3.  Quiescent human hematopoietic stem cells in the bone marrow niches organize the hierarchical structure of hematopoiesis.

Authors:  Takashi Yahata; Yukari Muguruma; Shizu Yumino; Yin Sheng; Tomoko Uno; Hideyuki Matsuzawa; Mamoru Ito; Shunichi Kato; Tomomitsu Hotta; Kiyoshi Ando
Journal:  Stem Cells       Date:  2008-09-11       Impact factor: 6.277

Review 4.  Stem cells, cancer, and cancer stem cells.

Authors:  T Reya; S J Morrison; M F Clarke; I L Weissman
Journal:  Nature       Date:  2001-11-01       Impact factor: 49.962

5.  Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer.

Authors:  Sharmila A Bapat; Avinash M Mali; Chaitanyananda B Koppikar; Nawneet K Kurrey
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

Review 6.  The cancer stem cell: premises, promises and challenges.

Authors:  Hans Clevers
Journal:  Nat Med       Date:  2011-03       Impact factor: 53.440

7.  Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.

Authors:  Paul P Szotek; Rafael Pieretti-Vanmarcke; Peter T Masiakos; Daniela M Dinulescu; Denise Connolly; Rosemary Foster; David Dombkowski; Frederic Preffer; David T Maclaughlin; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-18       Impact factor: 11.205

Review 8.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications.

Authors:  Tsukasa Shibue; Robert A Weinberg
Journal:  Nat Rev Clin Oncol       Date:  2017-04-11       Impact factor: 66.675

9.  Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.

Authors:  T Baba; P A Convery; N Matsumura; R S Whitaker; E Kondoh; T Perry; Z Huang; R C Bentley; S Mori; S Fujii; J R Marks; A Berchuck; S K Murphy
Journal:  Oncogene       Date:  2008-10-06       Impact factor: 9.867

10.  Expression of CD133-1 and CD133-2 in ovarian cancer.

Authors:  G Ferrandina; G Bonanno; L Pierelli; A Perillo; A Procoli; A Mariotti; M Corallo; E Martinelli; S Rutella; A Paglia; G Zannoni; S Mancuso; G Scambia
Journal:  Int J Gynecol Cancer       Date:  2007-09-13       Impact factor: 3.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.